Third Trillion $ pickI would love to hear the thoughts any of you may have on Teekas (Palm Beach) third trillion dollar pick. 5 small players in the psychedelic drug industry with the cure for PTSD and anxiety and …. Well everything ?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
There are a number of psychedelic drug companies that are self promoting, and in the micro cap space. I’m interested in the pre-ipo stock he keeps baiting us to subscribe to his service.
EI.VENTURES
Ei.ventures. Valuation: Pre-IPO, in the process of raising capital $50M. Pipeline: None. Molecule: Natural psilocybin extract. It claims to hold the Intellectual Property (IP) for the extraction process of two other botanical API compounds, DMT and MDMA. First it intend to fully develop Psilly (psilocybin extract) and our other botanical psychedelic formulations to potentially help those with chronic mental illness. Second, it will be developing a line of medicinal mushroom nutraceuticals for the consumer market. It is “Ground-floor opportunity” for retail investors at $4.94 per share. Minimum 1 share to invest. Success depends on raising capital from retail investors. Average Financial Analyst: N/A.
Sorry minimum is 100 share = $494.00
i WOULD LIKE TO KNOW TOO BUT HIS SERVICE IS 2000.00
IPO is EI.VENTURES
Here you go. The Teeka’s magic mushroom stocks are.
MYCOF buy up to .75
LKYSF buy up to $1.50
PRXTF buy up to .50
MNMD buy up to $5.00
CLXPF buy up to $3.00
Freebie CMPS
Thanks
Compass (CMPS). Valuation: $1.4B. Pipeline: Pre-clinical to Phase 2(b) for Treatment Resitant (TRD). Molecule: Psilocybin. Well-funded (2nd biggest psychedelic company next to Atai Life Sciences (ATAI) $2.6B. Compass is backed by Big Investors like Peter Theil. The FDA has fast-tracked this research by granting it Breakthrough Therapy Designation and it is the most advanced psilocybin clinical trials. It therefore has the potential to be the first to market a psilocybin drug. Psilocybin and MDMA seem today to be in a neck-to-neck contest to be first to cross the finish line on the Road to Legalization and FDA drug approval. Compass is however a “one trick pony” – success dependent on its only molecule. Average Financial Analyst 1 yr Target Price: $72.88. 2x upside.
Thanks for all the work. Well done. Seems you have a gift for this.
In your spare time try ENZC and NBIO both have been in gumhoe
Cybin (CLXPF). Valuation: $440M. Pipeline: Pre-clinical to Phase 2 for Alcohol Abuse, Psychiatric and Neurologic Disorders. Unlike Compass trial for TRD, Cybin’s psilocybin-based therapy is for major depressive disorder (MDD), a significantly larger patient population. Molecule: Psilocybin, triptomene, Phenethylamine. Like Mind Medicine, Cybin has multiple shots on goal. Cybin boast of 50+ proprietary compounds (DMT, Psilocybin, MDMA). It will need to raise capital to finance expensive clinical trials. Average Financial Analyst 1 yr Target Price: $9.5. 3x upside.
Numinus (LKYSF). Valuation: $168M. Pipeline: Phase 1 to assess the safety and psychoactive properties of a Psilocybe mushroom. Molecule: Natural psilocybin extract. Other trials – Canada compassionate access trials: MDMA compassionate access trial (with MAPS) for treatment resistant PTSD and psilocybin compassionate access trial for substance use (opioid, stimulant and/or alcohol use) disorders. The Multidisciplinary Association for Psychedelic Studies (MAPS) is currently in a well-funded Phase 3 clinical trial for MDMA-assisted psychotherapy to treat PTSD. It has also received Breakthrough Therapy Designation. Numinus is a fully integrated psychedelic healthcare provider. Psychotherapy Clinics are operational and revenue generating. The first successful harvest and extraction of Psilocybe mushrooms and Canada’s first public company license to cultivate and extract from psilocybin. Proven leadership to raise capital. It also will need to raise capital to finance expensive clinical trials. Average Financial Analyst 1 yr Target Price: No analyst covering stock.
Mydecine (MYCOF). Valuation: $94M. Pipeline: Phase 2A clinical on PTSD and smoking cessation. Molecule: pure psilocybin from mushroom, tryptamine, entactogenic compound similar to MDMA. Like Numinus, Mydecine is also fully integrated psychedelic company legally license to import/export/research psilocybin mushroom to psychotherapy treatment. Mydecine R&D team has made groundbreaking advances in psilocybin research with the discovery of over 40 compounds with pharmacological potential in mushrooms. Unlike Numinus brick and mortar psychotherapy clinics, Mydecine will focus on a virtual telehealth for psychedelic remote therapy which it believes is highly scalable worldwide. Like Numinus It also will need to raise capital to finance expensive clinical trials. Average Financial Analyst 1 yr Target Price: Roth Capital Partners 1 yr Target Price: $2.50. 6x upside.
Pure Extracts (PRXTF). Valuation: $32M. Pipeline: None. Molecule: None. Pure Extracts is a plant-based extraction company focused on cannabis, hemp, functional mushrooms (reishi and maitake) and now wants to expand to the rapidly emerging psychedelic sector. Wants to be position itself to be source of consistent quality plant based psychedelic mushroom to industry players planning to undertake clinical trials and research. Average Financial Analyst 1 yr Target Price: $0.90. 3x upside.
Mind Medicine (MNMD). Valuation: $1B Third Biggest by Market Cap among psychedelic stocks. Pipeline: Pre-clinical to Phase 2(b) for Anxiety, ADHD, Opioid addiction. Molecule: LSD and Ibogaine. Well-funded and also backed big investors like Kevin O’leary. Unlike Compass, MNMD has multiple shots on goal. MNMD has expansive molecules in pre-clinical LSD, LSD neutralizer in case of adverse reaction to LSD, MDMA, DMT, Psilocybin. MNMD stock price has more than 15x. Average Financial Analyst 1 yr target Price: $5.00. 1.5x upside.
Snooping around, i came across this psychedelics biotech VC fund with several scientists on the board, Palo Santo:
https://palosanto.vc/
I like that one of their stated goals is to support the science (with it’s potential medical and societal improvements). I’m considering giving it a little support, whether i make money or not.
The ideas of addiction treatments and reducing prison recidivism rates are not new. Dr. Timothy Leary had found and published strong evidence for these in the 1960’s.